John Hussman's CORT Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 31,500 shares of Corcept Therapeutics Incorporated (CORT) worth $1.1 M, representing 0.26% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in CORT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 87,500 shares. Largest reduction occurred in Q3 2018, reducing 125,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Corcept Therapeutics Incorporated (CORT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corcept Therapeutics Incorporated (CORT) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | -10,500 | Reduce 25.00% | 31,500 | $83.11 |
| Q3 2024 | -63,000 | Reduce 60.00% | 42,000 | $46.28 |
| Q2 2024 | +21,000 | Add 25.00% | 105,000 | $32.49 |
| Q1 2024 | +31,500 | Add 60.00% | 84,000 | $25.19 |
| Q4 2023 | -10,500 | Reduce 16.67% | 52,500 | $32.48 |
| Q3 2023 | -30,600 | Reduce 32.69% | 63,000 | $27.24 |
| Q2 2023 | -18,000 | Reduce 16.13% | 93,600 | $22.25 |
| Q1 2023 | +18,600 | Add 20.00% | 111,600 | $21.66 |
| Q4 2022 | -31,000 | Reduce 25.00% | 93,000 | $20.31 |
| Q3 2022 | -15,500 | Reduce 11.11% | 124,000 | $25.64 |
| Q2 2022 | +87,500 | Add 168.27% | 139,500 | $23.78 |
| Q4 2021 | -103,000 | Reduce 66.45% | 52,000 | $19.81 |
| Q3 2021 | +62,000 | Add 66.67% | 155,000 | $19.68 |
| Q2 2021 | +21,000 | Add 29.17% | 93,000 | $22.00 |
| Q1 2021 | -71,500 | Reduce 49.83% | 72,000 | $23.79 |
| Q4 2020 | -111,500 | Reduce 43.73% | 143,500 | $26.16 |
| Q3 2020 | +75,000 | Add 41.67% | 255,000 | $17.40 |
| Q2 2020 | +26,000 | Add 16.88% | 180,000 | $16.82 |
| Q1 2020 | +51,500 | Add 50.24% | 154,000 | $11.89 |
| Q4 2019 | +41,204 | Add 67.22% | 102,500 | $12.10 |
| Q3 2019 | +61,296 | New Buy | 61,296 | $14.13 |
| Q3 2018 | -125,000 | Sold Out | 0 | $0.00 |
| Q2 2018 | +125,000 | New Buy | 125,000 | $15.72 |
John Hussman's Corcept Therapeutics Incorporated Investment FAQs
John Hussman first purchased Corcept Therapeutics Incorporated (CORT) in Q2 2018, acquiring 125,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Corcept Therapeutics Incorporated (CORT) for 28 quarters since Q2 2018.
John Hussman's largest addition to Corcept Therapeutics Incorporated (CORT) was in Q2 2018, adding 125,000 shares worth $1.96 M.
According to the latest 13F filing for Q4 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 31,500 shares of Corcept Therapeutics Incorporated (CORT), valued at approximately $1.1 M.
As of the Q4 2025 filing, Corcept Therapeutics Incorporated (CORT) represents approximately 0.26% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Corcept Therapeutics Incorporated (CORT) was 255,000 shares, as reported at the end of Q3 2020.